Semaglutide and tirzepatide have become the most talked-about tools in weight management in a generation — and unlike a lot of what circulates in wellness culture, the headlines here are largely backed by some of the largest randomized controlled trials ever run in obesity medicine. Here's what the data actually shows, including the parts that don't make it into the marketing.

How GLP-1 Medications Work

Semaglutide is a GLP-1 receptor agonist — it mimics a hormone your gut naturally releases after eating, which signals the brain to reduce hunger and increase satiety. Tirzepatide goes a step further, acting on both the GLP-1 and GIP receptors, which appears to produce a more synergistic effect on appetite, food intake, and metabolic function.

What the Trials Show: Semaglutide

The pivotal STEP 1 trial (large randomized, placebo-controlled human trial) found that semaglutide 2.4 mg reduced body weight by roughly 15% over about 68 weeks, compared to 2–3% with placebo, primarily by changing hunger and satiety signaling. Semaglutide also has outcomes data beyond weight: the SELECT cardiovascular outcomes trial demonstrated a reduction in major adverse cardiovascular events in adults with cardiovascular disease and overweight or obesity — evidence tirzepatide doesn't yet have, since its own cardiovascular outcomes trial (SURMOUNT-MMO) isn't expected to report until 2027.

What the Trials Show: Tirzepatide

In the SURMOUNT-1 trial (randomized, placebo-controlled human trial), tirzepatide produced substantially greater weight loss than semaglutide has shown in its own trials. That difference was confirmed directly in SURMOUNT-5, the first head-to-head comparison of the two drugs: over 72 weeks, tirzepatide produced a mean weight loss of 20.2%, compared to 13.7% with semaglutide, with more than 80% of tirzepatide participants losing at least 10% of their body weight.

Retatrutide: Promising, But Still Investigational

Retatrutide is a triple agonist — it acts on GLP-1, GIP, and glucagon receptors, adding a mechanism aimed at increasing energy expenditure and liver fat oxidation on top of appetite suppression. In its Phase 2 trial (randomized, placebo-controlled human trial, published in the New England Journal of Medicine), the 12 mg dose produced a mean weight reduction of 24.2% at 48 weeks, versus 2.1% with placebo — the largest effect size seen among this drug class to date. It's important to be transparent here: retatrutide is not yet FDA-approved for weight loss. It remains in Phase 3 registrational trials (the TRIUMPH program), with results continuing to read out through 2026. The early data is genuinely exciting, but it's still investigational, not an established standard of care the way semaglutide and tirzepatide are.

The Part That Doesn't Get Said Enough: What Happens When You Stop

This is the most important, least-discussed finding in the research. The STEP 1 extension trial (human clinical follow-up study) found that within one year of stopping semaglutide, participants regained roughly two-thirds of the weight they had lost, along with a reversal of the cardiometabolic improvements gained during treatment. A similar pattern was observed after stopping tirzepatide in the SURMOUNT-4 trial. A broader systematic review and meta-analysis confirmed this isn't drug-specific — it's a pattern across the GLP-1 class. The clinical conclusion researchers draw from this isn't that the drugs "stop working" — it's that obesity behaves as a chronic condition, and these medications currently function more like ongoing management than a finite course of treatment, similar to how blood pressure or cholesterol medication works for many patients.

What This Means for a Real Program

The clinical trial data supports two things clearly: these medications produce weight loss that's difficult to achieve through lifestyle change alone, and stopping them without a plan tends to reverse much of that progress. That's exactly why medical oversight matters here — not just for prescribing the medication, but for building a sustainable plan around it, monitoring for side effects, and having an honest conversation about what maintenance looks like long after the first few months of visible results.

Calibrate IV's medical weight loss programs are physician-guided from intake through ongoing monitoring, with FDA-approved GLP-1 medications shipped directly to you. Book a consultation to find out which program — and which conversation about long-term maintenance — is right for you.